Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis
Authors' conclusion
In patients with T2DM and hypertension, the addition of henagliflozin to standard therapy over 6 months was associated with significant attenuation of adverse ventricular remodeling-as evidenced by reductions in LVMI, left atrial diameter, and diastolic filling indices-alongside clinically meaningful improvements in glycemic control, blood pressure, and body weight.
Study context
- Population
- Patients with T2D and hypertension132 matched analysed
- Participants
- 183 patients
- Exposure
- Henagliflozin added to standard therapy vs standard therapy alone
- Henagliflozinn = 66
- Controln = 66reference
- Outcome
- Change in LVMI from baseline
- Follow-up
- 6 months
Methodological detailssingle-centre, 1:1 propensity-score matched
- Single-centre
- 1:1 propensity-score matched
Main finding
As reported in the abstract
Change in LVMI
Henagliflozin
- 2.62
mean · SD 13.00 · g/m²
Control
+ 4.35
mean · SD 15.88 · g/m²
Between-group P = 0.007
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Henagliflozin | Control | P value |
|---|---|---|---|
| Change in FPG · 6 months | - 0.97 mmol/L | + 0.16 mmol/L | P = 0.037 |
| Change in HbA1c · 6 months | - 0.42% | + 0.04% | P = 0.021 |
| Change in systolic BP · 6 months | - 9.45 mmHg | - 1.95 mmHg | P = 0.023 |
| Change in diastolic BP · 6 months | - 3.38 mmHg | 0.68 mmHg | P = 0.029 |
| Change in BMI · 6 months | - 0.45 kg/m² | 0.00 kg/m² | P = 0.023 |
- Echocardiographic parameters · 6 months
- between-group P = 0.035
- Echocardiographic parameters · 6 months
- P = 0.044
- Echocardiographic parameters · 6 months
- P = 0.030
- Echocardiographic parameters · 6 months
- P = 0.018
- Echocardiographic parameters · 6 months
- P = 0.045
Left ventricular mass index (LVMI) baseline and 6-month values · baseline to 6 months
- Henagliflozin: from 87.90 ± 18.32 to 85.28 ± 18.20 g/m²
- Control: from 83.46 ± 18.22 to 87.81 ± 16.53 g/m²
Original publication
Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis. Cardiovasc Diabetol. Published 11 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →